A multicenter phase I clinical trial (NCT04230265) to assess the universal CAR-T-cell platform (UniCAR) that was recently described to have efficient in vitro and in vivo activity against CD123+ AML is currently recruiting patients [16]. The gene discussed is IL3RA; the disease is acute myeloid leukemia.